Physician profile
Mitchell Berman
NPI 1639827389
$4,337.94
in general payments reported to CMS, 2019-2025
27 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $445 · 2023: $971 · 2024: $1,475 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,892.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $759.26 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $538.50 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $410.13 | 2022-2025 | Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $323.73 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $286.40 | 2022-2024 | Xarelto |
| Lilly USA, LLC | $272.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.49 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $189.57 | 2023-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $183.53 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $175.39 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $171.59 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $154.01 | 2024 | Voquezna |
| Pfizer INC. | $131.74 | 2024-2025 | |
| Esperion Therapeutics, INC. | $83.84 | 2024-2025 | Nexletol |
| Abbvie INC. | $80.61 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $64.97 | 2024-2025 | Apretude |
| Verity Pharmaceuticals INC. | $44.21 | 2024-2025 | Tlando |
| Sanofi-Aventis U.S. LLC | $34.60 | 2023 | |
| Ani Pharmaceuticals, INC. | $26.98 | 2023 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $25.87 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.27 | 2025 | Recorlev |
| Kowa Pharmaceuticals America, INC. | $20.09 | 2025 | Zoryve |
| Medicure Pharma INC. | $19.89 | 2025 | Zypitamag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.33 | 2023 | Jardiance |
| Currax Pharmaceuticals LLC | $17.45 | 2025 | Contrave |
| Novartis Pharmaceuticals Corporation | $16.46 | 2023 | |
| Acella Pharmaceuticals, LLC | $14.53 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.